<DOC>
	<DOCNO>NCT00529581</DOCNO>
	<brief_summary>The purpose study determine safety efficacy C105 treat cognitive deficit occur due multiple sclerosis .</brief_summary>
	<brief_title>A Study C105 Cognitive Dysfunction Persons With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Males/females least 18 year old &lt; 65 year old , capable understand comply protocol , include speak write fluent English least 9th grade education Clinically definite diagnosis per McDonald criterion Multiple Sclerosis confirm Investigator ( RelapsingRemitting Secondary Progressive ) Stable disease relapsefree &gt; 90 day verify Investigator Presence cognitive deficit measure score 1.5 SD SDMT ( oral version ) score 1.0 SD SDMT 1.0 SD either CVLTII ( total learn delay recall ) PASAT EDSS &lt; = 6.5 Standard score &gt; 79 WRAT4 Reading test Have give write informed consent prior studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice his/her future medical care Capable performing requirement neuropsychological test battery include least 20/70 near visual acuity near vision chart , correction ( i.e. , eyeglass ) allow If female , must neither pregnant breastfeeding must either ( ) &gt; 12 month postmenopausal surgically sterilize ( b ) must agree use acceptable method birth control ( include hormonal contraceptive , intrauterine device , barrier method condom , diaphragm , etc . spermicide ) duration study . Abstinence consider acceptable method birth control . Subjects memory deficit cause concomitant medication usage significant neurological/psychological disease , e.g. , Alzheimer 's disease , Parkinson 's disease , stroke , TIA , Multiinfarct dementia , Huntington 's disease , head trauma , chronic CNS infection Evidence medical cause dementia Evidence Major Depressive Disorder determine Beck Fast Screen core &gt; 3 clinician interview Use follow medication : Antipsychotic agent , Centrally act appetite suppression drug ( e.g. , sibutramine ) , CNS stimulants drug metabolize ( e.g. , amantadine , Concerta , methylphenidate , Adderall , ephedrine , selegiline ) , Strattera ( atomoxetine ) , Tricyclic antidepressant ( e.g. , amitriptyline ) , Herbal preparation include Ginkgo Biloba contain Ephedra stimulant , MAO inhibitor . Note : medication may exclude permit , depend length treatment stability dose Uncontrolled labile hypertension , clinically significant , unstable , major concomitant disorder determine Principal Investigator Active malignancy within one year study participation Known human immunodeficiency virus ( HIV ) Current diagnosis unstable glaucoma History myocardial infarction symptomatic Coronary Artery Disease Evidence ongoing ischemia uncontrolled atrial ventricular arrhythmia show ECG History epilepsy seizure disorder Clinically significant motor speech residual neurological deficit ( e.g. , hemiparesis , aphasia ) interfere completion study procedure Baseline clinical laboratory value indicative clinically significant comorbidity Significant recent history ( within past 12 month ) current drug alcohol abuse ( define DSMIV ) Known allergy hypersensitivity amphetamine sympathomimetic amine Participation clinical trial investigational drug within 30 day prior randomization In opinion Principal Investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>cognitive dysfunction</keyword>
	<keyword>Cognitive Dysfunction associate Multiple Sclerosis</keyword>
</DOC>